The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX expands its clinical-stage pipeline through its proprietary...
BEIJING, June 26, 2026 /PRNewswire/ -- The Green Agriculture Chain section of the fourth China International Supply Chain Expo (CISCE) brought together more than...
MUNICH, June 26, 2026 /PRNewswire/ -- Sunwoda, a full-scenario energy storage solution provider, participated in ees Europe 2026 in Munich, Germany, showcasing a broad...
KUWAIT CITY, June 25, 2026 /PRNewswire/ -- Action Energy Company K.S.C.P. (Bloomberg: ALFTAQA KK) (Reuters: ALFTAQA.KW) (Premier Market of Boursa Kuwait: ALFTAQA), Kuwait's leading...